The global acquired hemophilia treatment market is set to reach USD 2,700.9 million by 2025, growing at a CAGR of 3.1%. The clinical manifestation associated with acquired hemophilia is provoked or spontaneous unexplained bleeding with delayed activated partial thromboplastin time (aPTT) in patients with no previous hereditary association with coagulopathy. Researchers throughut the globe are actively enaged in developing guidelines for the accurate diagnosis of acquired hemophilia due to its overlapping clinical manifestations with other autoimmune disease. The exorbitant cost associated with the bypassing agents employed as hemostatic therapy to control bleeding episodes will hamper the acquired hemophilia treatment market growth.
Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/1037
North America is currently dominating the regional segment for acquired hemophilia treatment market. The key parameters responsible for its supreme market growth are rising public health awarness regarding autoimmune disease leading to early disease diagnosis and treatment. As per the latest research findings brought forward by the Center for Disease Control and Prevention (CDC), the prevalence rate of acquired hemophilia in the United States is 0.2 to 1 per million people. Affordable reimbursement scenario for medicines employed for treating acquired hemophilia in federally funded hemophilia care centers will further strenghten the market growth in the region. Europe represents 31.8% market share on account of presene of key players such as Baxter Healthcare Corporation, Shire, Plc., Novo Nordisk and GlxoSmithkline, Plc., wich determines the market growth in the region. Asia Pacific holds 16.4% market share and is keen to register rampant growth during the forecast period on account of rising prevalence of acquired hemophilia in elderly population and developing healthcare infrastructure.
The key biopharmaceutical companies actively engaged in the manufacturing of drugs employed for the treatment of acquired hemophilia are Baxter Healthcare Corporation, BioXcel Corporation, Genetech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva Pharmaceutical Industries Ltd.
Any Questions? Feel Free to Enquire Here. We will Put You on The Right @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1037
Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Account Manager – Global
3131 McKinney Ave Ste 600
Dallas, TX 75204
Email ID: firstname.lastname@example.org
Phone No.: +1 972-362 -8199